December 12, 2025

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 58.96% Potential Upside in the Biotech Sector

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is making waves in the biotech sector with its compelling growth prospects and innovative therapies targeting chronic endocrine and neurological diseases. With a market..

Savara, Inc. (SVRA) Stock Analysis: Strong Buy Ratings and 48.6% Upside Potential

Savara, Inc. (NASDAQ: SVRA) is gaining significant attention in the biotech investing community, thanks to its promising pipeline and robust analyst support. This clinical-stage biopharmaceutical company, headquartered in Langhorne, Pennsylvania,..

Geron Corporation (GERN) Stock Analysis: Exploring a 158.99% Upside Potential in Biotech

In the ever-evolving biotechnology sector, Geron Corporation (NASDAQ: GERN) presents a compelling investment opportunity with a potential upside of 158.99%. Headquartered in Foster City, California, this commercial-stage biopharmaceutical company is..

Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Powerhouse with 22% Upside Potential

Cogent Biosciences, Inc. (NASDAQ: COGT) is capturing investor attention with its impressive market cap of $6.15 billion and a promising potential upside of 22.15%. As a prominent player in the..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Uncovering the 159.76% Potential Upside

For investors with an appetite for the biotech sector, Vir Biotechnology, Inc. (NASDAQ: VIR) presents a compelling opportunity. With a market capitalization of $922.4 million, this clinical-stage biopharmaceutical company is..

Butterfly Network, Inc. (BFLY) Stock Analysis: A 27% Upside with Strong Buy Ratings in the Medical Device Arena

Butterfly Network, Inc. (NASDAQ: BFLY) is carving out a distinctive niche in the healthcare sector, specifically within the medical devices industry. Renowned for its innovative ultrasound imaging solutions, Butterfly Network..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Exploring a 31.61% Potential Upside Amid Strong Buy Ratings

OrthoPediatrics Corp. (NASDAQ: KIDS), a specialist in pediatric orthopedic medical devices, is making waves with a compelling 31.61% potential upside, as indicated by the average analyst target price. With its..

CeriBell, Inc. (CBLL) Stock Analysis: Strong Buy Ratings Amid 32% Potential Upside

Investors eyeing the healthcare sector may find CeriBell, Inc. (NASDAQ: CBLL) an intriguing opportunity. A relatively young player in the medical devices industry, CeriBell is making strides with its innovative..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Why Analysts See a 72.79% Upside Potential

Investors keeping an eye on the biotechnology sector may want to pay close attention to Bicara Therapeutics Inc. (NASDAQ: BCAX). This clinical-stage biopharmaceutical company, based in Boston, Massachusetts, is making..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Biotech Innovator with an 87% Potential Upside

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is capturing the attention of biotech investors with its innovative approach to addressing unmet medical needs through cell and exosome-based therapeutics. As a clinical-stage biotechnology..

Replimune Group, Inc. (REPL) Investor Outlook: Biotechnology Firm with 27% Upside Potential

Replimune Group, Inc. (NASDAQ: REPL), a promising contender in the biotechnology sector, is captivating investor interest with its innovative approach to cancer treatment. Specializing in oncolytic immunotherapies, Replimune is at..

ArriVent BioPharma, Inc. (AVBP) Investor Outlook: Exploring a Promising 65.22% Upside Potential

ArriVent BioPharma, Inc. (NASDAQ: AVBP), a burgeoning name in the biotechnology sector, is making waves with its innovative approach to cancer treatment. This clinical-stage biopharmaceutical company, founded in 2021 and..

Avadel Pharmaceuticals (AVDL) Stock Analysis: Navigating a Steady Path in the Biopharmaceutical Sector

Avadel Pharmaceuticals plc (NASDAQ: AVDL) stands as a prominent player in the healthcare sector, specifically within the niche of specialty and generic drug manufacturing. Headquartered in Dublin, Ireland, Avadel has..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating Healthcare Growth and Challenges

InnovAge Holding Corp. (NASDAQ: INNV) operates within the healthcare sector, focusing on medical care facilities through its innovative Program of All-Inclusive Care for the Elderly (PACE). With a market capitalization..

Oculis Holding AG (OCS) Investor Outlook: Biotech Stock Poised for 115% Upside Potential

Oculis Holding AG (OCS), a Switzerland-based biotechnology firm specializing in ophthalmic diseases, is gaining attention from investors with a promising outlook. With a market capitalization of $1.21 billion, Oculis finds..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Potential 40% Upside Captivates Investor Attention

Tyra Biosciences, Inc. (NASDAQ: TYRA), a burgeoning player in the biotechnology sector, is drawing significant interest from investors with a potential upside of 40.29%. As a clinical-stage company, Tyra is..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Potential 118% Upside in Biotech Vision Care

LENZ Therapeutics, Inc. (NASDAQ: LENZ), a promising player in the biotechnology sector, has captured the attention of investors with a potential upside of 118.37%. Operating within the healthcare industry, this..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 59% Upside Potential in the Biotech Sector

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company, has caught the attention of investors with its promising prospects in the biotechnology sector. Headquartered in New Haven, Connecticut, Trevi focuses..

Cronos Group Inc. (CRON) Investor Outlook: Evaluating the Cannabis Sector Leader Amidst a 6.10% Revenue Growth

Cronos Group Inc. (NASDAQ: CRON), a notable player in the healthcare sector, operates within the highly dynamic drug manufacturing industry, specifically focusing on specialty and generic cannabis products. Based in..

AnaptysBio, Inc. (ANAB) Stock Analysis: A 34.83% Potential Upside in the Biotech Sector

AnaptysBio, Inc. (NASDAQ: ANAB) stands out in the competitive biotechnology sector with its focus on delivering groundbreaking immunology therapeutics. Investors are keenly watching this San Diego-based company, as it currently..

Search

Funds

December 12, 2025

Search

Funds

December 12, 2025

FTSE 100

Funds